The Special Programme on Human Reproduction (HRP), also known as the Special Programme of Research, Development and Research Training in Human Reproduction, was a World Health Organization (WHO) endeavor. It resulted in the following marketed combined injectable contraceptives: * Estradiol cypionate/medroxyprogesterone acetate (EC/MPA; brand names Cyclofem, Lunelle; code names HRP-112, Cyclo-Provera) * Estradiol valerate/norethisterone enanthate (EV/NETE; brand name Mesigyna; code name HRP-102) And in the following never-marketed progestogen injectable contraceptives:
Property | Value |
---|---|
dbo:abstract |
|
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of |
|
is foaf:primaryTopic of |